A joint venture managed by the RMR group has obtained a refinance loan of $ 1 billion for a Life Science and Office campus of 1.1 million square foot in Boston that serves as the Vertex Pharmaceuticals headquarters. The company includes private institutional investors and diversified Healthcare Trust, which has a share interest of 10 percent.
A Consortium by Morgan Stanley, Bank of Montreal, Goldman Sachs and JP Morgan gave the five-year-old, only interest rate reduction, fixed interest with an interest of 5.59 percent.
The company will use the proceeds to retire an existing $ 620 million CMBS loan that was created by Morgan Stanley in 2016, with an expiration date in 2026 according to Yardi Research Data. Extra funds go to lease reserves and repatriation in cash.
This refinancing deal landed only one year after Vertex Pharmaceuticals ink ink and agreed to occupy the property until 2044. The first agreement was the largest such obligation in Boston at that time.
Read also: 6 most important trends that design the Life Science sector
The Campus debuted in 2013, built on Build-to-out basis for the pharmaceutical company. A year later, Diversified Healthcare Trust, formerly Senior Housing Properties Trust, paid $ 1.1 billion for the active and has since entered into a partnership with various investors. The Fallon Co. sold the property.
The head office of Vertex Pharmaceuticals consists of two 18 -storey buildings that include 556,105 and 526,312 square feet. The suffering Gold-certified high-rise buildings have floor plates ranging between 28,500 and 41,000 square base, as well as floor-to-ceiling windows and 60,000 square base of retail space.
Located on 50 Northern Ave. And 11 Fan Pier Blvd., the duo is in the Seaport District in Boston, where Fallon built a master-planned development of 3 million square feet in nine city blocks.
Dechert gave legal advice to the lenders, while Skadden, ARPs, Slate, Meagher & Flom served as counselors for the owners.
The Life Science market from Metro Boston has seen better days
Greater Boston’s Life Science Market continues to struggle with uncertainty, while the tenant of the tenant adapts to an increasing headwind. Total lobeasing activity clocked at 426,000 square feet during the second quarter, which marks the second lowest volume since June 2020 and resulting in 91,500 square foot negative absorption, according to one CBRE report.
Nevertheless, the demand from the laboratory space increased by 30 percent compared to the first three months of 2025, which settled at 2.4 million square feet in the second quarter, the report shows. Nevertheless, this increase was attributed to upcoming lease instead of organic growth.
The vacancy rate of the Space Laboratory was arranged at 25.8 percent, an increase of almost 10 percent on an annual basis, and will probably continue to rise because 790,000 square foot product is planned for delivery that is completely empty at the end of the year, the CBRE report reveals.
The appetite of investors remained largely modest, with only two laboratory rooms that are closed during the second quarter, shows the same source. Metlife real estate investments sold one of the assets for $ 33 million, a sharp decrease in $ 103 million that it paid to acquire the real estate on 4 Burlington Woods Drive in 2022.
#RMR #managed #NABS #Boston #Life #Science #Campus